Death ends BMS hep C drug

Analysts put weight on BMS in oncology
Analysts put weight on BMS in oncology

One death and a several patient hospitalizations of Phase II clinical trial patients has prompted Bristol-Myers Squibb to end development of its experimental hepatitis C drug, BMS-986094. The company idled the study August 1 because of a cardiac event among one of its patients. That patient has died. The company said in a statement that a total of 9 patients, including the patient who died, have been hospitalized.

BMS said in a statement that the cause of the unexpected medical problems has not been definitively established, but it does involve heart and kidney toxicity.

The experimental drug was a nucleotide polymerase inhibitor. The August 1 idling announcement triggered concerns about the mechanism, which is also being explored by other companies.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions